Gesynta Pharma AB secures 22 MSEK funding for completion of pre-clinical development of GS-248

26 February, 2018

Solna, Sweden – February 26, 2018 – Gesynta Pharma AB today announced completion of series A round of financing, intended to provide funds for completion of pre-clinical development of its lead candidate, GS-248. A consortium of seasoned life sciences investors will provide financial and strategic support to the development program and bring the company to its next pivotal milestone, to initiate clinical trials of GS-248 in 2019. In connection with this series A financing round, the experienced pharma executives Gunnar Olsson, MD/PhD and former Vice President & Head of Cardiovascular & Gastrointestinal Dis., Global R&D, Astrazeneca and Maarten de Château, MD/PhD, co-founder and former CEO of Cormorant Pharmaceuticals AB, has joined the Board of Directors of Gesynta Pharma AB.

“We are extremely pleased to see the commitment of our current and new owners to providing the resources needed to prepare GS-248 for a first clinical trial. Our strategy is to quickly demonstrate clinical proof-of-concept for mPGES-1 modulation in novel indications, and the addition of financial resources and top-notch pharmaceutical board expertise is a prerequisite to progress effectively” says Patric Stenberg, CEO of Gesynta Pharma AB.

GS-248 is part of the OX-MPI development program which Gesynta Pharma AB acquired from Swedish pharmaceutical company Orexo AB last year. GS-248 is a highly selective inhibitor of the inducible enzyme microsomal prostaglandin E synthase 1 (mPGES-1) implicated in a broad range of inflammatory conditions. In the coming year, the focus will be to confirm its safety and tolerability in preclinical studies and to manufacture material for a clinical development program targeting niche indications in chronic inflammation.

For further information, please contact:

Gesynta Pharma AB Patric Stenberg, CEO
Tel: + 46 (0)733 836670 E-mail: patric.stenberg@gesynta.se

About Gesynta Pharma AB
Gesynta Pharma AB is a privately held Swedish company located in Stockholm. Based on research from Karolinska Institutet, and with initial innovation support from Karolinska Institutet Innovations AB, NovoNordisk and Vinnova, Gesynta Pharma AB leverages expertise in arachidonic acid research to explore niche indications in chronic inflammation for mPGES-1 inhibitors. The strategy of the company is to gain clinical proof of concept within such indications before seeking a partner able to achieve the full commercial potential of multiple therapeutic uses. Maintaining a lean organization, Gesynta Pharma AB is being actively managed by its founders and board members, who contribute extensive experience in the fields of drug development, legal and business, as well as mPGES-1 and medical research. For more information about Gesynta Pharma AB, please visit www.gesynta.se.

Download PDF

More news

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our reputable board holds vast experience in drug development, commercialization and company scale-up.

Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.

Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.

Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.